CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 6 enrolled
Drug / intervention
ADVM-043genetic
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02168686
NCT02168686Phase 2Completed
CompareCT.gov

Phase 1/2 Study of Intravenous or Intrapleural Administration of a Serotype rh.10 Replication Deficient Adeno-associated Virus Gene Transfer Vector Expressing the Human Alpha-1 Antitrypsin cDNA to Individuals With Alpha-1 Antitrypsin Deficiency

Adverum Biotechnologies, Inc.·interventional·Posted Jun 20, 2014·Updated Oct 5, 2023

In Brief

A Phase 2 clinical trial evaluating ADVM-043 for Alpha 1-Antitrypsin Deficiency. Completed, enrolled 6 participants across 2 sites.

Detailed Summary

The ADVANCE study is being conducted by Adverum Biotechnologies, Inc. as an open-label, multicenter, dose-escalation study in order to assess the safety and protein expression of ADVM-043 following a single intravenous or intrapleural administration.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlpha 1-Antitrypsin Deficiency
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJun 20, 2014
Enrollment StartNov 28, 2017
Primary CompletionAug 29, 2019
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 12.0 years ago

Interventions

ADVM-043genetic

Gene transfer vector administration